While highly active antiretroviral therapy remains one of the great triumphs of HIV/AIDS research and has resulted in a significant decrease in morbidity and mortality, it requires life-long adherence and is associated with significant toxicities and cost. Antiretroviral therapy alone cannot eradicate HIV;accordingly, new approaches are required to understand the mechanisms by which HIV persists during therapy and to identify interventions that can eradicate the virus from the body of an infected person. We have established an international Collaboratory of academic and industry investigators who have a long and successful track record of collaborating with others to conceive, implement, and complete innovative research projects relevant to characterizing viral persistence and exploring interventions to eradicate the virus. The Administrative Core will ensure that the scientific vision that unifies the Collaboratory is enacted in all the projects and cores, and reflected in the research that is produced. The Core's functions are especially important because our Collaboratory integrates researchers across several international locations as well as multiple institutions within the United States.
The specific aims of the Administrative Core are: 1) to provide an organizational and programmatic structure;2) to provide organizational and financial oversight and planning, set priorities, and establish a decision-making process;3) to ensure efficient data, information and resource sharing;and 4) to establish a mechanism for expanding the current Collaboratory.
These aims will be achieved by employing a range of technologies to support regular, efficient communications and information sharing between the steering committee, executive committee, Scientific Advisory Panel, and all participants in the Collaboratory. The methodologies proposed here will maximize the productive participation of all members of the Collaboratory and provide a platform on which data gathered within projects and cores will inform the activities of other components of the Collaboratory.
We have established an international Collaboratory of academic and industry investigators who have a long and successful track record of collaborating with each other on research designed to undestand why HIV persists and how it can be eradicated from the body of an infected person. The Administrative Core will facilitate interactions between the investigators and support the planning, conduct, and evaluation of the Collaboratory's research activities.
|Wang, Xiao Qian; Palmer, Sarah (2018) Single-molecule techniques to quantify and genetically characterise persistent HIV. Retrovirology 15:3|
|Okoye, Afam A; Hansen, Scott G; Vaidya, Mukta et al. (2018) Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nat Med 24:1430-1440|
|Winckelmann, Anni; Morcilla, Vincent; Shao, Wei et al. (2018) Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals. AIDS 32:1793-1802|
|Wykes, Michelle N; Lewin, Sharon R (2018) Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 18:91-104|
|Lee, Sulggi A; Elliott, Julian H; McMahon, James et al. (2018) Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. Clin Pharmacol Ther :|
|Kumar, Nitasha A; van der Sluis, Renee M; Mota, Talia et al. (2018) Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4+ T Cells. J Immunol 201:1468-1477|
|Walters, Lucy C; Harlos, Karl; Brackenridge, Simon et al. (2018) Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. Nat Commun 9:3137|
|Adland, Emily; Hill, Matilda; Lavandier, Nora et al. (2018) Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. J Virol 92:|
|Boyer, Zoe; Palmer, Sarah (2018) Targeting Immune Checkpoint Molecules to Eliminate Latent HIV. Front Immunol 9:2339|
|Wang, Chia-Ching; Thanh, Cassandra; Gibson, Erica A et al. (2018) Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. Blood Adv 2:3479-3482|
Showing the most recent 10 out of 190 publications